Telik Presents Results At ASCO From Assist-5 Trial Of Telcyta In Platinum Refractory And Resistant Ovarian Cancer

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

Telik, Inc. announced presentation at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, of results from the ASSIST-5 Phase 3 randomized, multinational study of TELCYTA(R) (canfosfamide HCl) in combination with pegylated liposomal doxorubicin (PLD) vs. PLD alone in second-line therapy in platinum refractory or resistant ovarian cancer.

 

0 Comments

You must be logged in to post comments.

We care about your feedback. Let us know how we can improve your CancerCompass experience.